bioMérieux: 1H26 preview: BARC -2.1%/-1.6% vs BBG sales/CEBIT; Expect FY26 guidance reiterated

Research evidence excerpt

bioMérieux: 1H26 preview: BARC -2.1%/-1.6% vs BBG sales/CEBIT; Expect FY26 guidance reiterated

Barclays | bioMérieux

merchantability or fitness for a particular purpose or use with respect to any data included in this publication. To the extent that this publication states

on the front page that it is intended for institutional investors and is not subject to all of the independence and disclosure standards applicable to debt

research reports prepared for retail investors under U.S. FINRA Rule 2242, it is an “institutional debt research report” and distribution to retail investors

is strictly prohibited. Barclays also distributes such institutional debt research reports to various issuers, media, regulatory and academic

organisations for their own internal informational news gathering, regulatory or academic purposes and not for the purpose of making investment

decisions regarding any debt securities. Media organisations are prohibited from re-publishing any opinion or recommendation concerning a debt

issuer or debt security contained in any Barclays institutional debt research report. Any such recipients that do not want to continue receiving Barclays

institutional debt research reports should contact debtresearch@barclays.com. Unless clients have agreed to receive “institutional debt research

reports” as required by US FINRA Rule 2242, they will not receive any such reports that may be co-authored by non-debt research analysts. Eligible

clients may get access to such cross asset reports by contacting debtresearch@barclays.com. Barclays will not treat unauthorized recipients of this

report as its clients and accepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are